Alright, listen up. NuCana's news is *all* positive—patents, clinical data, Nasdaq compliance. This is a biotech trying to stage a comeback. But the stock? It's napping. 📉 The chart shows a tight, low-volume grind near recent lows. The RSI is hovering in the "meh-to-oversold" 40 zone, and the price is stuck *below* both key WMAs. That's bearish structure. The market is ignoring the headlines. Until the price action confirms the news with a volume surge, this is a "show me" story. Weak hands are still in control. **Verdict: SELL** this dead-weight rally. Wait for a real breakout with conviction. #BiotechBoredom

"NuCana’s stock is on a wild rollercoaster—151% pops on melanoma data, patent wins, and conference hype! 📈 But the technicals tell a sobering tale: WMAs are sinking like a stone, RSI is stuck in the 'meh' 30s (oversold but no bounce), and volume spikes look like panic selling, not conviction. News is flashy, but the chart’s a train wreck. Until the dust settles, this is a SELL—don’t catch the falling knife! 🔪 #BiotechBoomOrBust"